Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:AEZ
CUSIPN/A
Phone+1-843-9003223
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,996.27%
Return on Equity-3,046.52%
Return on Assets-164.23%
Miscellaneous
EmployeesN/A
Outstanding Shares11,671,000
AEterna Zentaris (TSE:AEZ) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AEZ."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (TSE:AEZ) released its earnings results on Monday, May, 7th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $1.22. The biopharmaceutical company had revenue of $31.17 million for the quarter, compared to analyst estimates of $2.57 million. AEterna Zentaris had a negative return on equity of 3,046.52% and a negative net margin of 3,996.27%. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Carolyn Egbert, Independent Chairman of the Board
- Michael Ward, President, Chief Executive Officer, Director
- James Clavijo, Chief Financial Officer (Age 52)
- Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
- Jude Dinges, Chief Commercial Officer, Senior Vice President (Age 58)
- Eckhard G. Gunther Ph.D., Vice President - Alliance Management
- Michael Teifel, Vice President - Non-Clinical Sciences
- John W. Sharkey Ph.D., Business Development Consultant (Age 60)
- Philip Allen Theodore, Corporate Secretary (Age 64)
- David A. Dodd, Director (Age 65)
Has AEterna Zentaris been receiving favorable news coverage?
Media coverage about AEZ stock has trended somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.48 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of AEterna Zentaris?
Shares of AEZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZ stock can currently be purchased for approximately C$2.11.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of C$34.20 million.
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223.
MarketBeat Community Rating for AEterna Zentaris (AEZ)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
